Matrix Laboratories Ltd (Mumbai Stock Exchange, 524794; National Stock Exchange, MATRIXLABS), announced today that Matrix Laboratories NV, a Belgian limited corporation controlled by it, acquired 4,644,512 shares in Docpharma as a result of the public take-over bid which closed on 28 September 2005, thereby raising its shareholding up to 95.51%. Payment of the offer price of EUR 34.00 per share will occur on [13] October 2005.

In accordance with article 513 of the Belgian Companies Code, and as announced in the prospectus, Matrix Laboratories NV will bring a public squeeze-out bid for all remaining Docpharma shares which were not tendered. The squeeze-out bid runs from [12] October until [2 November] 2005 (including), and is made on the same terms, i.e. EUR 34.00 per Docpharma share, coupon no. 1 and the following attached.

After expiry of the public squeeze-out bid, the shares which have not been tendered, will be deemed to have been transferred to Matrix Laboratories NV, with consignation of the offer price. At the date of closing of the Squeeze-out Bid ([2 November] 2005), after close of trading, the Docpharma shares will be delisted from Euronext Brussels.

Formal announcement of the results of the public take-over bid, as well as formal announcement of the squeeze-out bid, will be published tomorrow, 5 October, in the Belgian financial press.

Prospectus:

The prospectus and the acceptance form can be obtained free of charge from Fortis Bank through the following telephone number: 0800/90301.

The prospectus will also be available, for information purposes only, on the following websites:
www.fortisbank.be/beleggen,
www.docpharma.be, en from 31 August 2005.